Is DMK Pharmaceuticals Corp. overvalued or undervalued?

As of 15 August 2016, DMK Pharmaceuticals Corp. has moved from a grade of does not qualify to risky, indicating a significant shift in its valuation outlook. The company is currently assessed as overvalued given its negative P/E ratio of -0.0001 and an EV to EBITDA of 0.36, which are stark contrasts to its peers. Notably, the company's ROCE stands at an impressive 162.55% and ROE at 358.09%, yet these high returns do not compensate for the underlying valuation concerns.
In comparison to its peers, such as Inhibikase Therapeutics, which has a P/E of -3.4299, and Pulmatrix, Inc. with a P/E of -2.4446, DMK Pharmaceuticals Corp. appears to be in a precarious position. The negative EV to Sales ratio of -1.82 further underscores the challenges the company faces in generating revenue relative to its enterprise value. Overall, the combination of these ratios suggests that DMK Pharmaceuticals Corp. is overvalued in the current market environment.